Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER+ breast cancer.

Shee K, Jiang A, Varn FS, Liu S, Traphagen NA, Owens P, Ma CX, Hoog J, Cheng C, Golub TR, Straussman R, Miller TW.

FASEB J. 2018 Aug 30:fj201801241R. doi: 10.1096/fj.201801241R. [Epub ahead of print]

PMID:
30161001
2.

Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.

Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, He X, Kosaka Y, Matsunuma R, Crowder R, Hoog J, Phommaly C, Goncalves R, Ramalho S, Peres RMR, Punturi N, Schmidt C, Bartram A, Jou E, Devarakonda V, Holloway KR, Lai WV, Hampton O, Rogers A, Tobias E, Parikh PA, Davies SR, Li S, Ma CX, Suman VJ, Hunt KK, Watson MA, Hoadley KA, Thompson EA, Chen X, Kavuri SM, Creighton CJ, Maher CA, Perou CM, Haricharan S, Ellis MJ.

Cell Rep. 2018 Aug 7;24(6):1434-1444.e7. doi: 10.1016/j.celrep.2018.07.009.

3.

Confidence intervals for proportion ratios of stratified correlated bilateral data.

Zhuang T, Tian GL, Ma CX.

J Biopharm Stat. 2018 Jul 16:1-23. doi: 10.1080/10543406.2018.1489405. [Epub ahead of print]

PMID:
30010492
4.

Male Breast Cancer: An Updated Surveillance, Epidemiology, and End Results Data Analysis.

Liu N, Johnson KJ, Ma CX.

Clin Breast Cancer. 2018 Jun 27. pii: S1526-8209(18)30016-8. doi: 10.1016/j.clbc.2018.06.013. [Epub ahead of print]

PMID:
30007834
5.

[Enhanced Antibiotic Resistant Bacteria Removal from Wastewater Treatment Plant by Different Disinfection Technologies].

Liu YL, Ma CX, Ding HZ, Qiu Y, Li B, Wang S, Li J.

Huan Jing Ke Xue. 2017 Oct 8;38(10):4286-4292. doi: 10.13227/j.hjkx.201612141. Chinese.

PMID:
29965213
6.

Common risk difference test and interval estimation of risk difference for stratified bilateral correlated data.

Shen X, Ma CX, Yuen KC, Tian GL.

Stat Methods Med Res. 2018 Jan 1:962280218781988. doi: 10.1177/0962280218781988. [Epub ahead of print]

PMID:
29916335
7.

Improvement in Gastrointestinal Symptoms After Cognitive Behavior Therapy for Refractory Irritable Bowel Syndrome.

Lackner JM, Jaccard J, Keefer L, Brenner DM, Firth RS, Gudleski GD, Hamilton FA, Katz LA, Krasner SS, Ma CX, Radziwon CD, Sitrin MD.

Gastroenterology. 2018 Jul;155(1):47-57. doi: 10.1053/j.gastro.2018.03.063. Epub 2018 Apr 25.

PMID:
29702118
8.

A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.

O'Shaughnessy J, DeMichele A, Ma CX, Richards P, Yardley DA, Wright GS, Kalinsky K, Steis R, Diab S, Kennealey G, Geschwindt R, Jiang W, Rugo HS.

Breast Cancer Res Treat. 2018 Aug;170(3):547-557. doi: 10.1007/s10549-018-4770-6. Epub 2018 Apr 19.

PMID:
29675680
9.

The deep lymphatic anatomy of the hand.

Ma CX, Pan WR, Liu ZA, Zeng FQ, Qiu ZQ.

Ann Anat. 2018 Jul;218:105-109. doi: 10.1016/j.aanat.2018.03.001. Epub 2018 Apr 3.

PMID:
29625252
10.

Enhanced antitumor effects of radiotherapy combined local nimustine delivery rendezvousing with oral temozolomide chemotherapy in glioblastoma patients.

Yang DY, Bu XY, Zhou ZL, Yan ZY, Ma CX, Qu MQ, Zhao YW, Kong LF, Wang YW, Luo JC.

J Cancer Res Ther. 2018 Jan;14(1):78-83. doi: 10.4103/jcrt.JCRT_844_17.

11.

Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers.

Mundt F, Rajput S, Li S, Ruggles KV, Mooradian AD, Mertins P, Gillette MA, Krug K, Guo Z, Hoog J, Erdmann-Gilmore P, Primeau T, Huang S, Edwards DP, Wang X, Wang X, Kawaler E, Mani DR, Clauser KR, Gao F, Luo J, Davies SR, Johnson GL, Huang KL, Yoon CJ, Ding L, Fenyö D, Ellis MJ, Townsend RR, Held JM, Carr SA, Ma CX.

Cancer Res. 2018 May 15;78(10):2732-2746. doi: 10.1158/0008-5472.CAN-17-1990. Epub 2018 Feb 22.

PMID:
29472518
12.

Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer.

Dehdashti F, Wu N, Bose R, Naughton MJ, Ma CX, Marquez-Nostra BV, Diebolder P, Mpoy C, Rogers BE, Lapi SE, Laforest R, Siegel BA.

Breast Cancer Res Treat. 2018 Jun;169(3):523-530. doi: 10.1007/s10549-018-4696-z. Epub 2018 Feb 13.

PMID:
29442264
13.

[The influence of EphA2 overexpression on proliferation and apoptosis of human lens epithelial cells exposed to high-concentration dexamethasone in vitro].

Ma CX, Zheng GY.

Zhonghua Yan Ke Za Zhi. 2018 Feb 11;54(2):125-132. doi: 10.3760/cma.j.issn.0412-4081.2018.02.011. Chinese.

PMID:
29429298
14.

[Effect of Warm Acupuncture on the Levels of Serum Immunoglobulin E, Interleukin-1 β and Tumor Necrosis Factor-α in Rats with Allergic Rhinitis].

Zheng XL, Tian YP, Luo HY, Zhao YD, Liu XY, Jiang Y, Ma CX, Wang MJ, Liu M.

Zhen Ci Yan Jiu. 2018 Jan 25;43(1):35-8. doi: 10.13702/j.1000-0607.170064. Chinese.

PMID:
29383892
15.

[Wound repair and functional reconstruction of high-voltage electrical burns in wrists].

Shen YM, Ma CX, Qin FJ, Zhang C, Wang C, Hu XH.

Zhonghua Shao Shang Za Zhi. 2017 Dec 20;33(12):738-743. doi: 10.3760/cma.j.issn.1009-2587.2017.12.004. Chinese.

PMID:
29275614
16.

Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent.

Marquez-Nostra BV, Lee S, Laforest R, Vitale L, Nie X, Hyrc K, Keler T, Hawthorne T, Hoog J, Li S, Dehdashti F, Ma CX, Lapi SE.

Oncotarget. 2017 Nov 1;8(61):104303-104314. doi: 10.18632/oncotarget.22228. eCollection 2017 Nov 28.

17.

Genome-wide association study for grain yield and related traits in elite wheat varieties and advanced lines using SNP markers.

Wang SX, Zhu YL, Zhang DX, Shao H, Liu P, Hu JB, Zhang H, Zhang HP, Chang C, Lu J, Xia XC, Sun GL, Ma CX.

PLoS One. 2017 Nov 27;12(11):e0188662. doi: 10.1371/journal.pone.0188662. eCollection 2017.

18.

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.

Bagegni N, Thomas S, Liu N, Luo J, Hoog J, Northfelt DW, Goetz MP, Forero A, Bergqvist M, Karen J, Neumüller M, Suh EM, Guo Z, Vij K, Sanati S, Ellis M, Ma CX.

Breast Cancer Res. 2017 Nov 21;19(1):123. doi: 10.1186/s13058-017-0913-7.

19.

[Effects of flap or myocutaneous flap combined with fascia lata or composite mesh on repairing severe high-voltage electrical burn wounds in abdomen of patients].

Zhang C, Hu XH, Chen H, Ma CX, Qin FJ, Wen CQ, Shen YM.

Zhonghua Shao Shang Za Zhi. 2017 Oct 20;33(10):602-606. doi: 10.3760/cma.j.issn.1009-2587.2017.10.003. Chinese.

PMID:
29056021
20.

A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.

Ma CX, Suman V, Goetz MP, Northfelt D, Burkard ME, Ademuyiwa F, Naughton M, Margenthaler J, Aft R, Gray R, Tevaarwerk A, Wilke L, Haddad T, Moynihan T, Loprinzi C, Hieken T, Barnell EK, Skidmore ZL, Feng YY, Krysiak K, Hoog J, Guo Z, Nehring L, Wisinski KB, Mardis E, Hagemann IS, Vij K, Sanati S, Al-Kateb H, Griffith OL, Griffith M, Doyle L, Erlichman C, Ellis MJ.

Clin Cancer Res. 2017 Nov 15;23(22):6823-6832. doi: 10.1158/1078-0432.CCR-17-1260. Epub 2017 Sep 5.

PMID:
28874413
21.

Negative-Pressure Ventilation in Pediatric Acute Respiratory Failure.

Hassinger AB, Breuer RK, Nutty K, Ma CX, Al Ibrahim OS.

Respir Care. 2017 Dec;62(12):1540-1549. doi: 10.4187/respcare.05531. Epub 2017 Aug 31.

PMID:
28860332
22.

CDK4/6 inhibition triggers anti-tumour immunity.

Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, Khan N, Ubellacker JM, Xie S, Metzger-Filho O, Hoog J, Ellis MJ, Ma CX, Ramm S, Krop IE, Winer EP, Roberts TM, Kim HJ, McAllister SS, Zhao JJ.

Nature. 2017 Aug 24;548(7668):471-475. doi: 10.1038/nature23465. Epub 2017 Aug 16.

23.

Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.

Haricharan S, Punturi N, Singh P, Holloway KR, Anurag M, Schmelz J, Schmidt C, Lei JT, Suman V, Hunt K, Olson JA Jr, Hoog J, Li S, Huang S, Edwards DP, Kavuri SM, Bainbridge MN, Ma CX, Ellis MJ.

Cancer Discov. 2017 Oct;7(10):1168-1183. doi: 10.1158/2159-8290.CD-16-1179. Epub 2017 Aug 11.

PMID:
28801307
24.

[Effects of flow-through descending branch of lateral circumflex femoral artery flap on repairing high-voltage electrical burn wounds of wrist of patients].

Shen YM, Chen X, Zhang C, Wang C, Qin FJ, Ma CX, Hu XH.

Zhonghua Shao Shang Za Zhi. 2017 Jul 20;33(7):422-425. doi: 10.3760/cma.j.issn.1009-2587.2017.07.006. Chinese.

PMID:
28763908
25.

Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.

Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D.

NPJ Breast Cancer. 2016 Dec 14;2:16037. doi: 10.1038/npjbcancer.2016.37. eCollection 2016.

26.

NCCN Guidelines Insights: Antiemesis, Version 2.2017.

Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, Kirkegaard S, Kloth DD, Lagman R, Lim D, Loprinzi C, Ma CX, Maurer V, Michaud LB, Nabell LM, Noonan K, Roeland E, Rugo HS, Schwartzberg LS, Scullion B, Timoney J, Todaro B, Urba SG, Shead DA, Hughes M.

J Natl Compr Canc Netw. 2017 Jul;15(7):883-893. doi: 10.6004/jnccn.2017.0117.

PMID:
28687576
27.

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.

Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, Winer E, Naughton M, Goetz MP, Russell C, Tripathy D, Cobleigh M, Forero A, Pluard TJ, Anders C, Niravath PA, Thomas S, Anderson J, Bumb C, Banks KC, Lanman RB, Bryce R, Lalani AS, Pfeifer J, Hayes DF, Pegram M, Blackwell K, Bedard PL, Al-Kateb H, Ellis MJC.

Clin Cancer Res. 2017 Oct 1;23(19):5687-5695. doi: 10.1158/1078-0432.CCR-17-0900. Epub 2017 Jul 5.

PMID:
28679771
28.

The role of neratinib in HER2-driven breast cancer.

Cherian MA, Ma CX.

Future Oncol. 2017 Jun 30. doi: 10.2217/fon-2017-0186. [Epub ahead of print]

PMID:
28665682
29.

Discovery of efficient stimulators for adult hippocampal neurogenesis based on scaffolds in dragon's blood.

Liang JH, Yang L, Wu S, Liu SS, Cushman M, Tian J, Li NM, Yang QH, Zhang HA, Qiu YJ, Xiang L, Ma CX, Li XM, Qing H.

Eur J Med Chem. 2017 Aug 18;136:382-392. doi: 10.1016/j.ejmech.2017.05.025. Epub 2017 May 10.

PMID:
28525839
30.

Breast cancer stage variation and survival in association with insurance status and sociodemographic factors in US women 18 to 64 years old.

Hsu CD, Wang X, Habif DV Jr, Ma CX, Johnson KJ.

Cancer. 2017 Aug 15;123(16):3125-3131. doi: 10.1002/cncr.30722. Epub 2017 Apr 25.

31.

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083.

Somlo G, Frankel PH, Arun BK, Ma CX, Garcia AA, Cigler T, Cream LV, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vahdat LT, Goetz MP, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow KV, Chen AP, Ruel C, Newman EM, Gandara DR, Weitzel JN.

Clin Cancer Res. 2017 Aug 1;23(15):4066-4076. doi: 10.1158/1078-0432.CCR-16-2714. Epub 2017 Mar 29.

32.

64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.

Lee H, Shields AF, Siegel BA, Miller KD, Krop I, Ma CX, LoRusso PM, Munster PN, Campbell K, Gaddy DF, Leonard SC, Geretti E, Blocker SJ, Kirpotin DB, Moyo V, Wickham TJ, Hendriks BS.

Clin Cancer Res. 2017 Aug 1;23(15):4190-4202. doi: 10.1158/1078-0432.CCR-16-3193. Epub 2017 Mar 15.

33.

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.

Ma CX, Gao F, Luo J, Northfelt DW, Goetz M, Forero A, Hoog J, Naughton M, Ademuyiwa F, Suresh R, Anderson KS, Margenthaler J, Aft R, Hobday T, Moynihan T, Gillanders W, Cyr A, Eberlein TJ, Hieken T, Krontiras H, Guo Z, Lee MV, Spies NC, Skidmore ZL, Griffith OL, Griffith M, Thomas S, Bumb C, Vij K, Bartlett CH, Koehler M, Al-Kateb H, Sanati S, Ellis MJ.

Clin Cancer Res. 2017 Aug 1;23(15):4055-4065. doi: 10.1158/1078-0432.CCR-16-3206. Epub 2017 Mar 7.

34.

Autoantibodies against glucose-regulated protein 78 as serological biomarkers in metastatic and recurrent hepatocellular carcinoma.

Ying X, Han SX, He CC, Zhou CY, Dong YP, Cai MJ, Sui X, Ma CX, Sun X, Zhang YY, Gou WL, Mason C, Zhu Q.

Oncotarget. 2017 Apr 11;8(15):24828-24839. doi: 10.18632/oncotarget.15192.

35.

Cloning and Characterization of TaTGW-7A Gene Associated with Grain Weight in Wheat via SLAF-seq-BSA.

Hu MJ, Zhang HP, Liu K, Cao JJ, Wang SX, Jiang H, Wu ZY, Lu J, Zhu XF, Xia XC, Sun GL, Ma CX, Chang C.

Front Plant Sci. 2016 Dec 20;7:1902. doi: 10.3389/fpls.2016.01902. eCollection 2016.

36.

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).

Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, DeSchryver K, Crouch E, Brink A, Watson M, Luo J, Tao Y, Barnes M, Dowsett M, Budd GT, Winer E, Silverman P, Esserman L, Carey L, Ma CX, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther JM, Dayao Z, Ota D, Leitch M, Olson JA Jr, Allred DC, Hunt K.

J Clin Oncol. 2017 Apr 1;35(10):1061-1069. doi: 10.1200/JCO.2016.69.4406. Epub 2017 Jan 3.

37.

[Reconstruction of perineal obliteration deformity after extensive deep burn with ilioinguinal flap].

Shen YM, Ma CX, Qin FJ, Wang C, Du WL, Zhang C.

Zhonghua Shao Shang Za Zhi. 2016 Dec 20;32(12):709-713. doi: 10.3760/cma.j.issn.1009-2587.2016.12.002. Chinese.

PMID:
28043293
38.

Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians.

Ademuyiwa FO, Tao Y, Luo J, Weilbaecher K, Ma CX.

Breast Cancer Res Treat. 2017 Feb;161(3):491-499. doi: 10.1007/s10549-016-4062-y. Epub 2016 Dec 3.

39.

Combination of endogenous neural stem cell mobilization and lithium chloride treatment for hydrocephalus following intraventricular hemorrhage.

Yuan Q, Bu XY, Yan ZY, Liu XZ, Wei ZY, Ma CX, Qu MQ.

Exp Ther Med. 2016 Nov;12(5):3275-3281. Epub 2016 Oct 4.

40.

The JAZF1-SUZ12 fusion protein disrupts PRC2 complexes and impairs chromatin repression during human endometrial stromal tumorogenesis.

Ma X, Wang J, Wang J, Ma CX, Gao X, Patriub V, Sklar JL.

Oncotarget. 2017 Jan 17;8(3):4062-4078. doi: 10.18632/oncotarget.13270.

41.

Primary cilium is required for the stimulating effect of icaritin on osteogenic differentiation and mineralization of osteoblasts in vitro.

Ma XN, Ma CX, Shi WG, Zhou J, Ma HP, Gao YH, Xian CJ, Chen KM.

J Endocrinol Invest. 2017 Apr;40(4):357-366. doi: 10.1007/s40618-016-0568-8. Epub 2016 Oct 21.

PMID:
27770387
42.

Polysaccharides from Polygonatum Inhibit the Proliferation of Prostate Cancer-Associated Fibroblasts.

Han SY, Hu MH, Qi GY, Ma CX, Wang YY, Ma FL, Tao N, Qin ZH.

Asian Pac J Cancer Prev. 2016;17(8):3829-33.

43.

Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.

Rajput S, Khera N, Guo Z, Hoog J, Li S, Ma CX.

Oncotarget. 2016 Aug 30;7(35):56864-56875. doi: 10.18632/oncotarget.10870.

44.

[Clinical analysis of aphakic glaucoma following infantile congenital cataract surgery].

Ma CX, Lü Y, Lü J, Yang L, Tan FL, Li BB.

Zhonghua Yi Xue Za Zhi. 2016 Jul 19;96(27):2176-8. doi: 10.3760/cma.j.issn.0376-2491.2016.27.014. Chinese.

PMID:
27464545
45.

The Feasibility of Using Metacognitive Strategy Training to Improve Cognitive Performance and Neural Connectivity in Women with Chemotherapy-Induced Cognitive Impairment.

Wolf TJ, Doherty M, Kallogjeri D, Coalson RS, Nicklaus J, Ma CX, Schlaggar BL, Piccirillo J.

Oncology. 2016;91(3):143-52. doi: 10.1159/000447744. Epub 2016 Jul 23.

46.

Chemotherapy principles of managing stage IV breast cancer in the United States.

Hernandez-Aya LF, Ma CX.

Chin Clin Oncol. 2016 Jun;5(3):42. doi: 10.21037/cco.2016.04.01. Epub 2016 Apr 14. Review.

47.

[Research Progress on the Genomics of Taenia solium and Candidate Vaccines for Cysticercosis].

Ma CX, Wang HW, Yang YX.

Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2016 Apr;34(2):161-5. Chinese.

PMID:
30124252
48.

Testing equality of proportions for correlated binary data in ophthalmologic studies.

Ma CX, Liu S.

J Biopharm Stat. 2017;27(4):611-619. doi: 10.1080/10543406.2016.1167072. Epub 2016 Mar 24.

PMID:
27010613
49.

Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer.

Ma CX, Bose R, Ellis MJ.

Adv Exp Med Biol. 2016;882:125-54. doi: 10.1007/978-3-319-22909-6_5. Review.

PMID:
26987533
50.

A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.

Ma CX, Sanchez C, Gao F, Crowder R, Naughton M, Pluard T, Creekmore A, Guo Z, Hoog J, Lockhart AC, Doyle A, Erlichman C, Ellis MJ.

Clin Cancer Res. 2016 Jun 1;22(11):2650-8. doi: 10.1158/1078-0432.CCR-15-2160. Epub 2016 Jan 18.

Supplemental Content

Support Center